Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Rezolute, Inc.RZLT · healthcare
GradeNonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required
Reliability0.83 AUCfailure model, filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate1.07% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$12.5M to $120M assetstotal assets $112.8M[1]
Warningsshort runway, thin data · fortress balance sheetnot computable: degenerate inputs
Inputs computable6 of 14
Graded fromfilings received through Sep 24, 202615 days before the rescan; every figure keyed to the SEC receipt date
Last close$4.632026-10-08; market equity $448.3M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$5$10NovDecJanFebMarAprMayJunJulAugSepOct$4.64
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Nov 21, 2012nonen/aQ1
Sep 21, 2021nonen/aQ2
Sep 21, 2022nonen/aQ3
Sep 26, 2026nonen/aQ2

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Sep 24, 2026; the document on sec.gov.

Rezolute, Inc. (“Rezolute”, the “Company”, “we” or “us”) is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (“HI”). Our lead clinical asset, ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle.

Warnings [top]

Short runway. cash runway is 2.0 months[2]
Thin data. 6 of 14 grade factors are computable; minimum is 7
Fortress balance sheet. cash minus debt is 27,079,000 USD; Altman Z is not used[3-4]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 44.2
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(9.0%)[1,5-7](6.6%)44.28112026-06-30
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 43.1
Twelve-month failure probability0.11%0.07%60.32482026-06-30
Altman Z double-prime(4.40)[1,8-13](0.31)51.77562026-06-30
Net debt to EBITDAnot computable1.82x
EBITDA must exceed $100,000
Interest coveragenot computable(4.51x)
latest aligned inputs end 2021-06-30; latest annual assets end 2026-06-30
Current ratio9.68x[8-9]2.96x17.48392026-06-30
Growth and financing, sleeve percentile 53.2
Revenue growth, three-year compoundnot computable10.0%
four annual observations are required; found 0
Free cash flow growth, three-year compoundnot computable10.9%
four consecutive annual FCF observations are required; found 3
Reinvestment ratenot computable37.1%
one or more required annual facts are missing
Asset growth, three years(3.0%)[1,7,14-15]2.1%58.97042026-06-30
Net share issuance, one year6.5%[16-17]2.5%47.66342026-09-21

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month(50.1%)8.0%14hotter than 14 of 100 peers
Distance from 52-week high(57.6%)(31.4%)19closer to its high than 19 of 100 peers
EBIT to enterprise value(18.3%)(1.5%)24pricier than 76 of 100 peers
Free cash flow yield(9.9%)(1.0%)31pricier than 69 of 100 peers
Book value to price0.220.2844pricier than 56 of 100 peers
Sales to pricenot computable0.31required accounting or market input is missing
Composite equity issuance, five years241.8%20.3%93more equity-funded than 93 of 100 peers
Relative strength against the sector, log excess return(0.91)(0.14)14ahead of 14 of 100 peers

Inputs: market equity $448.8M; EBIT -$83.0M; free cash flow -$44.6M; book equity $100.7M; debt $14.3M; cash $10.6M[16].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2026-06-30
Return on assets above zero(44.2%)✗ fail[5,7]
Operating cash flow above zero-$64.6M✗ fail[6]
Return on assets improved11.8 pts✓ pass[5,7,14,18]
Operating cash flow exceeds net income$13.0M✓ pass[5-6]
Long-term leverage felln/a[1,7,14]
Current ratio improved(468.9 pts)✗ fail[8-9,19-20]
No new shares issued6.5%✗ fail[16-17]
Gross margin improvedn/a
Asset turnover improvedn/a[7,14]
Cash, filings, liquidity
Cash and equivalents$10.6M[2]
Operating cash flow, four quarters-$64.6M[2,6,21-23]
Months of runway2.0
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing15
10-K received Sep 24, 2026
Median daily dollar volume$5.7M
63 sessions
Days since newest grade input15

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$112.8M2026-06-302026-09-2410-Kfiling · viewer · series
2cashus-gaap:CashAndCashEquivalentsAtCarryingValue$10.6M2026-06-302026-09-2410-Kfiling · viewer · series
3cashus-gaap:CashAndCashEquivalentsAtCarryingValue$41.0M2021-06-302022-09-1510-Kfiling · viewer · series
4total debtus-gaap:LongTermDebt$14.0M2021-06-302022-09-1510-Kfiling · viewer · series
5net incomeus-gaap:NetIncomeLoss-$77.6M2026-06-302026-09-2410-Kfiling · viewer · series
6operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$64.6M2026-06-302026-09-2410-Kfiling · viewer · series
7assetsus-gaap:Assets$175.5M2025-06-302026-09-2410-Kfiling · viewer · series
8current assetsus-gaap:AssetsCurrent$110.5M2026-06-302026-09-2410-Kfiling · viewer · series
9current liabilitiesus-gaap:LiabilitiesCurrent$11.4M2026-06-302026-09-2410-Kfiling · viewer · series
10retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$481.4M2026-06-302026-09-2410-Kfiling · viewer · series
11operating incomeus-gaap:OperatingIncomeLoss-$83.0M2026-06-302026-09-2410-Kfiling · viewer · series
12book equityus-gaap:StockholdersEquity$100.7M2026-06-302026-09-2410-Kfiling · viewer · series
13liabilitiesus-gaap:Liabilities$12.2M2026-06-302026-09-2410-Kfiling · viewer · series
14assetsus-gaap:Assets$132.7M2024-06-302025-09-1710-Kfiling · viewer · series
15assetsus-gaap:Assets$123.7M2023-06-302024-09-1910-Kfiling · viewer · series
16shares outstandingdei:EntityCommonStockSharesOutstanding96,722,3332026-09-212026-09-2410-Kfiling · viewer · series
17shares outstandingdei:EntityCommonStockSharesOutstanding90,811,3682025-09-152025-09-1710-Kfiling · viewer · series
18net incomeus-gaap:NetIncomeLoss-$74.4M2025-06-302026-09-2410-Kfiling · viewer · series
19current assetsus-gaap:AssetsCurrent$171.1M2025-06-302026-09-2410-Kfiling · viewer · series
20current liabilitiesus-gaap:LiabilitiesCurrent$11.9M2025-06-302026-09-2410-Kfiling · viewer · series
21operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$51.5M2026-03-312026-05-1210-Qfiling · viewer · series
22operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$37.8M2025-12-312026-02-1210-Qfiling · viewer · series
23operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$17.4M2025-09-302025-11-0610-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.